{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-300558","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2021-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.144631+00:00","generated_at":"2026-06-28T20:21:06.190605+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cullinan Oncology CEO Owen Hughes departs; Nadim Ahmed appointed as new President and CEO","bullets":["CEO Owen Hughes departs Oct 18, 2021; gets 12 months base salary, pro-rata bonus of $216,507, and accelerated vesting.","Nadim Ahmed appointed CEO, President, and Board member effective Oct 18; previously President of Hematology at BMS.","Ahmed receives $600k base salary, $625k sign-on bonus, 2.71M stock options, and performance RSUs.","Hughes will serve as Strategic Advisor for up to 12 months; noncompetition and nondisclosure covenants apply.","Company reaffirms Pearl update expected in Q4 2021; no change to pipeline plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-300558","json":"https://secwatch.observer/filing/0001193125-21-300558.json","markdown":"https://secwatch.observer/filing/0001193125-21-300558.md","text":"https://secwatch.observer/filing/0001193125-21-300558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/0001193125-21-300558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/d66778d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T20:21:06.190605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f53c36dc1","claim":"Owen Hughes departed as President and Chief Executive Officer at Cullinan Therapeutics, Inc..","evidence_excerpt":"Mr. Hughes’ last date of employment with the Company as its President and Chief Executive Officer is October 18, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/0001193125-21-300558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"456b322948","claim":"Nadim Ahmed was appointed as Class III Director at Cullinan Therapeutics, Inc..","evidence_excerpt":"the Board appointed Mr. Ahmed as a Class III director of the Company, effective as of October 18, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/0001193125-21-300558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"a26bded1e5","claim":"Nadim Ahmed was appointed as President and Chief Executive Officer at Cullinan Therapeutics, Inc..","evidence_excerpt":"the Board appointed Nadim Ahmed as President and Chief Executive Officer of the Company, effective as of October 18, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/0001193125-21-300558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}